Our news
NeoPhore raises an additional £9.6m (USD $12.2m) Series B financing extension to further progress drug discovery pipeline
NeoPhore raises an additional £9.6m (USD $12.2m) Series B financing extension to further progress drug discovery pipeline • Italian investors, NE…
NeoPhore presented a first disclosure of NP1867 at AACR-NCI-EORTC Conference in Boston, USA
On Saturday October 14th, at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference in Boston, USA NeoPhore presented a first…
NeoPhore signs research collaboration with The Institute of Cancer Research, London
London, UK, 18 April 2023, – NeoPhore Limited, a small molecule neoantigen immuno-oncology company, today announces that it has signed a strategic c…
NeoPhore completes extension to Series B financing to further advance discovery pipeline
Scientific milestones achieved significantly ahead of schedule Cambridge, UK, 19 January 2023 – NeoPhore Limited, a small molecule neoantigen i…
Other news
BioCentury's Emerging Company Profile
CEO Jeff Roix spoke to BioCentury about how NeoPhore Ltd is developing small molecules to inhibit DNA mismatch repair (MMR) and create a pool of…
‘Big place’ for small-molecule booster drugs in cancer immunotherapy, says NeoPhore CEO
APM Health: Interview with CEO, Jeff Roix
NeoPhore Enters Immuno-Oncology Fray With DNA-Repair Technology
Scrip Emerging company profile: UK-based NeoPhore, founded in 2017, is developing novel cancer therapies based on DNA-repair technology. The company…